posted on 2016-08-17, 00:00authored byElizabeth
G. Gibson, McKenzie M. King, Susan L. Mercer, Joseph E. Deweese
Topoisomerase II
is an essential nuclear enzyme involved in regulating
DNA topology to facilitate replication and cell division. Disruption
of topoisomerase II function by chemotherapeutic agents is in use
as an effective strategy to fight cancer. Etoposide is an anticancer
therapeutic that disrupts the catalytic cycle of topoisomerase II
and stabilizes enzyme-bound DNA strand breaks. Etoposide is metabolized
into several species including active quinone and catechol metabolites.
Our previous studies have explored some of the details of how these
compounds act against topoisomerase II. In our present study, we extend
those analyses by examining several effects of etoposide quinone on
topoisomerase IIα including whether the quinone impacts ATP
hydrolysis, DNA ligation, cleavage complex persistence, and enzyme/DNA
binding. Our results demonstrate that the quinone inhibits relaxation
at 100-fold lower levels of drug when compared to that of etoposide.
Further, the quinone inhibits ATP hydrolysis by topoisomerase IIα.
The quinone
does appear to stabilize single-strand breaks similar to etoposide
suggesting a traditional poisoning mechanism. However, there is minimal
difference in cleavage complex persistence in the presence of etoposide
or etoposide quinone. In contrast to etoposide, we find that etoposide
quinone blocks enzyme/DNA binding, which provides an explanation for
previous data showing the ability of the quinone to inactivate the
enzyme over time. Finally, etoposide quinone is able to stabilize
the N-terminal protein clamp implying an interaction between the compound
and this portion of the enzyme. Taken together, the evidence supports
a two-mechanism model for the effect of the quinone on topoisomerase
II: (1) interfacial poison and (2) covalent poison that interacts
with the N-terminal clamp and impacts the binding of DNA.